Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data also suggest that PET-tau performs better than PET-amyloid in predicting the best validated AD diagnostic marker- the CSF total tau/Aβ ratio.
|
28800330 |
2017 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We secondarily hypothesized a third group characterized by either CSF tau pathology or neurodegeneration, in addition to amyloidosis (A+/N+ or Stage 2), would show lower neuropsychology scores than the amyloid positive group (A+/N- or Stage 1) when compared to the amyloid negative group.
|
28497179 |
2017 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic models were constructed by Cox proportional hazards regression with patient characteristics (age, sex, and Mini-Mental State Examination [MMSE] score), magnetic resonance imaging (MRI) biomarkers (hippocampal volume, normalized whole-brain volume), cerebrospinal fluid (CSF) biomarkers (amyloid-β1-42, tau), and combined biomarkers.
|
29049480 |
2017 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined whether neuropsychiatric symptoms (NPS) interact with cerebrospinal fluid (CSF) biomarkers (amyloid-β42 [Aβ42], tau, phosphorylated tau181 [ptau181], tau/Aβ42, and ptau181/Aβ42) of Alzheimer's disease pathology to predict driving decline among cognitively-normal older adults (N = 116) aged ≥65.
|
28453487 |
2017 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although blood biomarkers have not yet proven useful, cerebrospinal fluid (CSF) biomarkers (low amyloid-β42, high t-tau, and high p-tau) effectively contribute to AD diagnoses in the general population and are increasingly used in clinical practice.
|
28413821 |
2017 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Decreased levels of CSF Aβ<sub>40</sub> and Aβ<sub>42</sub> occur before HCHWA-D mutation carriers develop clinical symptoms, implicating vascular deposition of both Aβ species as early steps in cerebral amyloid angiopathy pathogenesis.
|
27903811 |
2017 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the cognitive profile of healthy individuals with increased Cardiovascular Risk Factors, Aging and Dementia (CAIDE) dementia risk score and to explore whether this association is related to vascular burden and CSF biomarkers of amyloidosis and neurodegeneration.
|
29898969 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To perform a meta-analysis of 4 core CSF biomarkers (β-amyloid [Aβ]42, Aβ40, total tau [t-tau], and phosphorylated tau [p-tau]) to assess which of these are most altered in sporadic cerebral amyloid angiopathy (CAA).
|
29386280 |
2018 |
Amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In an asymptomatic at-risk cohort, elevated CSF Aβ (with or without elevated tau) was associated with greater rates of cognitive decline, with the specific pattern of decline varying across cognitive measures.
|
29523644 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
When using the core CSF biomarkers (Aβ42, total Tau and phosphorylated Tau), 30% of the patients fell into the high-AD-likelihood (HL) group (both amyloid and neurodegeneration markers positive), 30% into the low-AD-likelihood group (all biomarkers negative), 28% into the suspected non-Alzheimer pathophysiology (SNAP) group (only neurodegeneration markers positive) and 12% into the isolated amyloid pathology group (only amyloid-positive).
|
29558986 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study confirms strong concordance between CSF biomarkers and PET Aβ-amyloid status is independent of immunoassay platform, supporting their utility as biomarkers in clinical practice for the diagnosis of AD and for participant enrichment in clinical trials.
|
29171991 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indeed, episodic disturbances can diminish CSF cerebral flow circulation increasing deposition in cerebral parenchyma of contrary metabolic products (e.g. beta Amyloid), possibly having a causal influence on senile dementia.
|
30037601 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compared CSF levels of biomarkers of amyloidosis (Aβ<sub>1-42</sub>) and neurodegeneration (p-Tau<sub>181</sub>) in individuals with aMCI and with subjective cognitive impairment (SCI) in order to ascertain diagnostic accuracy and predict the odds ratio associated with aMCI.
|
29017912 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients were classified as normal, amyloidosis (A+/N-), amyloidosis and neurodegeneration (A+/N+) or suspected non-AD pathophysiology (SNAP), according to their CSF levels of biomarkers.
|
29966201 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF proteins associated with AD clinical stages and progression can complement Aβ and tau markers to inform neurodegeneration.
|
30253800 |
2018 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Correction: Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia.
|
30365556 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
With a single molecule array method (Simoa, Quanterix), plasma NfL concentrations were measured in 99 subjects with AD at the stage of mild cognitive impairment (MCI-AD; n = 25) or at the stage of early dementia (ADD; n = 33), and in nondemented controls (n = 41); in all patients, the clinical diagnoses were in accordance with the results of the four core cerebrospinal fluid (CSF) biomarkers (amyloid β (Aβ)1-42, Aβ42/40, Tau, and pTau181), interpreted according to the Erlangen Score algorithm.
|
30055655 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The evaluation of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) (β-amyloid, t-tau, p-tau) can be used to estimate the risk of developing dementia in patients at the pre-clinical stages of AD, i.e. subjective cognitive decline (SCD) and mild cognitive impairment (MCI).
|
30509028 |
2018 |
Amyloidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CSF t-tau/Aβ<sub>1-42</sub> ratio had 100% specificity and 90% sensitivity for SYN + AD, and CSF Aβ<sub>1-42</sub> had 77% specificity and 82% sensitivity for neocortical SYN stage.
|
29467305 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the full sample, cortical [<sup>18</sup>F]AV1451 was associated with all CSF biomarkers, most strongly with p-tau (<i>r</i> = 0.75 vs 0.57 for t-tau and -0.49 for Aβ<sub>42</sub>).
|
29282337 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid (CSF) markers of neurodegeneration [neurofilament light chain (NFL), total Tau (T-Tau)], tau pathology [phosphorylated tau (p-Tau)], glial cell damage or activation [glial fibrillary acidic protein (GFAP)], and brain amyloidosis [β-amyloid 1-42 (Aβ42)] are useful for diagnosis and prognosis in several neurodegenerative disorders.
|
30248592 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
No association of ARHL with CSF or brain Aβ levels was found.
|
31118310 |
2019 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This may indicate that Aβ levels in the CSF are affected significantly by ventriculomegaly and not as much by pathophysiological pathways characteristic for each dementia entity.
|
29324921 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of Aβ and tau imaging in AD brain and CSF as well as blood biomarkers is shortly summarized.
|
30605056 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid (CSF) biomarkers amyloid-β1-42 peptide (Aβ1-42) and tau were used in order to differentiate AD from SNAP.
|
31201430 |
2019 |